ATEC
Alphatec Holdings, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | $21M | Q1 2026 call | — |
| ALIF ASP growth | 4% | Q1 2026 call | — |
| cervical ASP growth | 8% | Q1 2026 call | — |
| global EOS installed base growth | 7% | Q1 2026 call | — |
| lateral ASP growth | 2% | Q1 2026 call | — |
| new surgeon user growth | 23% | Q1 2026 call | — |
| non-GAAP R&D non-GAAP | $14M | Q1 2026 call | — |
| non-GAAP SG&A non-GAAP | $118M | Q1 2026 call | — |
| procedural volume growth | 21% | Q1 2026 call | — |
| U.S. EOS Edge installed base growth | 39% | Q1 2026 call | — |
| Free cash flow non-GAAP | $3M | full year | — |
| Non-GAAP adjusted EBITDA non-GAAP | $33M | Quarter Ended December 31, 2025 | — |
| Non-GAAP adjusted EBITDA margin non-GAAP | 16% | Quarter Ended December 31, 2025 | — |
| average revenue per procedure growth | 2% | Full Year Ended December 31, 2025 | — |
| cash balance | $161M | as of December 31, 2025 | — |
| surgical volume growth | 24% | Full Year Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATEC
this stock
Alphatec Holdings, Inc.
|
$1.45B | -54.5% | -15.4% | — | 9.7% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATEC | +7.4% | +17.8% | -45.1% | +10.8% | -54.5% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +6.0% | +13.8% | -54.2% | +9.7% | -65.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.